AlphaCentric Advisors LLC has filed a Form 13F-HR with the Securities and Exchange Commission, disclosing its equity holdings as of September 30, 2026. The filing lists 247 distinct positions held by the firm, managed by Robert Glass, who serves as Chief Compliance Officer.
The portfolio is diversified across various sectors, including healthcare, technology, and finance. Notable holdings include significant positions in Gilead Sciences Inc. with 21,278 shares, Sanofi SA Sponsored ADR with 15,345 shares, and Neurocrine Biosciences Inc. with 10,230 shares. The firm also holds substantial stakes in Prologis Inc. (2,019 shares) and First Majestic Silver Corp. (6,540 shares).
AlphaCentric holds a mix of individual common stocks and exchange-traded funds. ETF positions include the INVESCO Exchange Traded Fund Trust S&P 500 Buy Write with 23,771 shares and the ISHARES TR 1-3 Year Treasury Bond with 66,011 shares.
The filing indicates that the firm's total equity portfolio consists of these 247 positions, with the report signed by Robert Glass on November 2, 2026.
